High expression of proenkephalin is associated with favorable outcomes in patients with gastrointestinal stromal tumors

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research

Related Links:

AbstractGastrointestinal stromal tumours (GIST) are the most common gastrointestinal mesenchymal tumours of the gastrointestinal tract. They are diagnosed by the expression of markers like CD 117, CD 34, DOG-1 and PDGFRA. The identification of these mutations has resulted in a better understanding of their oncogenic mechanisms. Few studies have shown the high incidence of a second malignancy including papillary thyroid cancer (PTC) in known patients of GIST. Literature review on pathogenesis of GIST and PTC showed that PTC targeting Protein Kinase C theta (PKC θ) plays role in both PTC and GIST. Further studies have ...
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsTo the best of our knowledge, this is the first published report in which the c.1A  >  C; p.(Met1?) pathogenic variant in theSDHA is associated with a GIST.SDHA pathogenic variants increase the risk of paraganglioma, pheochromocytoma, GIST, pituitary adenoma and renal cancer in an autosomal dominant inherited condition named paraganglioma syndrome type 5. The absence of family history of tumors inSDHA pathogenic variants carriers could be related to its low penetrance. All patients diagnosed with WT GISTs should be referred to a hereditary cancer genetic counseling unit regardless of the age at ...
Source: Hereditary Cancer in Clinical Practice - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThe aim of this study is to assess treatment trends and overall survival (OS) in small bowel (SB) and colorectal (CR) gastrointestinal stromal tumors (GIST) with respect to the introduction of imatinib in 2008.MethodsPatients diagnosed with SB and CR GIST were identified from the National Cancer Database (2004 –2015). The primary outcome was 5- and 10-year OS. Patients were stratified by tumor site, time period (before and after imatinib), and treatment type. OS was analyzed using Kaplan-Meier survival curves, log-rank test, and Cox proportional hazards models.ResultsA total of 8441 cases were inclu...
Source: Journal of Gastrointestinal Surgery - Category: Surgery Source Type: research
CONCLUSION: This is the first report of bilateral sensorineural hearing loss induced by regorafenib. PMID: 31381817 [PubMed - as supplied by publisher]
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Pharm Ther Source Type: research
PMID: 31371309 [PubMed - in process]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionsOur findings identified DKK4 as a proper tumor biomarker for prognosis predicting and recurrence monitoring, and suggested a novel immune ‐escape mechanism driving malignancy in GIST, which might be a potential therapeutic target to improve the effects of canonical RTK therapy and combined immunotherapy.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Abstract Introduction: Sunitinib is a standard second-line treatment in advanced gastrointestinal stromal tumours (GIST). We aimed to search for predictive factors for grade 3 and 4 toxicity, progression-free survival (PFS) and overall survival (OS) in a GIST reference center patient population, outside clinical trials. Methods: A retrospective analysis was performed of patients treated in two European Comprehensive Cancer Centers between January 2005 and December 2015. Demographic and clinical features, tumour characteristics and biological parameters were investigated. Logistic regression models were used to fin...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
CONCLUSION: Known predictors for interest in CAM such as female gender, higher education and younger age do not seem to apply in cancer patients with no prior CAM affinity. This result together with a high CAM prevalence raises the importance of addressing CAM in all cancer patients for a need-oriented treatment and to avoid side effects and interactions with conventional treatment. PMID: 31331555 [PubMed - in process]
Source: Complementary Therapies in Medicine - Category: Complementary Medicine Authors: Tags: Complement Ther Med Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
CONCLUSIONS Anorectal GIST is a rare tumor that has a better outcome compared with GISTs arising at other sites in the gastrointestinal tract. PMID: 31326976 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
More News: Cancer | Cancer & Oncology | Gastroenterology | Gastrointestinal Stromal Tumor (GIST)